Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma
CONCLUSIONS: Gem/Doce demonstrates promising safety and efficacy as a renal-sparing treatment option for high-grade UTUC in appropriately selected patients.PMID:37805338 | DOI:10.1016/j.urolonc.2023.08.013
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Ian M McElree Alex Belzer Sarah L Mott Vignesh T Packiam Michael A O'Donnell Ryan L Steinberg Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Cytology | Dialysis | Docetaxel | Radiography | Taxotere | Upper Endoscopy | Ureter and Renal Pelvis Cancer | Urology & Nephrology